Genfit SA (GNFT) has released an update.
Genfit SA has announced the European Commission’s approval of Iqirvo (Elafibranor), a new treatment option for Primary Biliary Cholangitis. The approval follows the drug’s positive reception by the EMA and the U.S. FDA earlier this year. This milestone paves the way for a €26.5 million payment to Genfit, bolstering their efforts to develop treatments for severe liver diseases.
For further insights into GNFT stock, check out TipRanks’ Stock Analysis page.